Drug maker Sun Pharma today said it has received a tentative approval from US health regulator to sell a generic version of Crestor tablets, used in the treatment of various heart diseases, in the American market.
The company's US subsidiary has bagged a tentative approval for its abbreviated new drug application (ANDA) to market a generic version of IPR Pharmaceutical's Crestor tablets in strengths of 5 mg, 10 mg, 20 mg and 40 mg, Sun Pharma said in a statement.
Crestor has annual sales of nearly $3.4 billion in the US market. The generic Rosuvastatin tablets contain Rosuvastatin Calcium in strengths of 5 mg, 10 mg, 20 mg and 40 mg, it said.
The tablets are indicated in patients suffering with heart diseases like pertriglyceridemia and patients with homozygous familial hypercholesterolemia.
Shares of Sun Pharmaceutical Industries today closed at Rs 2,002.15 on the Bombay Stock Exchange, up 1.71 per cent from its previous close.
